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Objectives This study sought to evaluate the day–night variation of acute myocardial infarction (MI) in patients with obstruc-
tive sleep apnea (OSA).
Background Obstructive sleep apnea has a high prevalence and is characterized by acute nocturnal hemodynamic and
neurohormonal abnormalities that may increase the risk of MI during the night.
Methods We prospectively studied 92 patients with MI for which the time of onset of chest pain was clearly identified. The
presence of OSA was determined by overnight polysomnography.
Results For patients with and without OSA, we compared the frequency of MI during different intervals of the day based on
the onset time of chest pain. The groups had similar prevalence of comorbidities. Myocardial infarction occurred be-
tween 12 AM and 6 AM in 32% of OSA patients and 7% of non-OSA patients (p 0.01). The odds of having OSA in
those patients whose MI occurred between 12 AM and 6 AM was 6-fold higher than in the remaining 18 h of the day
(95% confidence interval: 1.3 to 27.3, p 0.01). Of all patients having an MI between 12 AM and 6 AM, 91% had OSA.
Conclusions The diurnal variation in the onset of MI in OSA patients is strikingly different from the diurnal variation in non-
OSA patients. Patients with nocturnal onset of MI have a high likelihood of having OSA. These findings suggest
that OSA may be a trigger for MI. Patients having nocturnal onset of MI should be evaluated for OSA, and future
research should address the effects of OSA therapy for prevention of nocturnal cardiac events. (J Am Coll
Cardiol 2008;52:343–6) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.0276
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ibstructive sleep apnea (OSA) is an increasingly preva-
ent condition that remains underdiagnosed and under-
reated (1). OSA may increase the risk of cardiovascular
iseases, including hypertension, ischemic heart disease,
troke, heart failure, pulmonary hypertension, and cardiac
rrhythmias (2,3). The prevalence of OSA is 2- to 3-fold
igher in patients with a history of myocardial infarction
MI) (4).
In the general population, MI and sudden cardiac death
SCD) occur with a diurnal periodicity that peaks between
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anto, Vitoria, Brazil; ‡International Clinical Research Center Brno and First
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as more frequent during the night in OSA patients (6).
echanisms of SCD could have included MI, stroke, arrhyth-
ias, pulmonary embolus, aortic dissection, or other cardio-
ascular causes.
Acute nocturnal pathophysiological responses to OSA, in-
luding hypoxemia, sympathetic activation, and surges in blood
ressure, may lead to plaque rupture, coronary thrombosis, and
I. Should OSA be a trigger of MI, we would expect a peak
f onset of symptoms of MI during the night. Whether OSA
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nocturnal MI has not been previ-
ously studied.
Methods
This study was approved by the
Institutional Review Board of
the Mayo Clinic, and all subjects
provided informed consent. We
prospectively studied 92 patients
admitted with incident MI to
our hospital. Although consecu-
tive patients were eligible, re-
cruitment was based on exclusion
riteria listed below, on availability of research personnel,
nd on patients consenting to participate. The exclusion
riteria were: patients without typical chest pain, uncertain
ime of onset of MI, and previous continuous positive
irway pressure treatment.
The diagnosis of MI was made by the patients’ attending
hysician and confirmed by the following: increase in
reatine-phosphokinase concentration 2 times the upper
imit of normal and elevation of troponin T activity (0.03
g/ml).
The time of onset of MI was determined by each patient’s
eport of the chest pain that prompted hospital admission.
his strategy for assessing the time of MI has been
reviously validated (7).
haracteristics of the Study Population at theime of MI, Acc rding to the Presence orbs n e of OSA
Table 1
Characteristics of the Study Population at the
Time of MI, According to the Presence or
Absence of OSA
Characteristics OSA (n  64) No OSA (n  28) p Value
Age (yrs) 64 12 57 12 0.02
Male gender (%) 78 75 0.7
Body mass index (kg/m2) 31 6 28 4 0.01
AHI (events/h) 22 2.1 1.6 0.3 0.0001
LVEF (%) 51 2 55 2 0.11
Peak CK (U/l) 1,392 296 1,417 264 0.9
Peak CK-MB (ng/ml) 143 23 134 20 0.8
Hypertension (%) 57 57 1
Hypercholesterolemia (%) 67 61 0.6
Diabetes mellitus (%) 25 11 0.1
Prior MI (%) 13 18 0.5
Congestive heart failure (%) 5 0 0.5
Current smoker (%) 27 39 0.2
Systolic BP (mm Hg)* 120 2 116 3 0.2
Diastolic BP (mm Hg)* 69 1 67 2 0.4
Cholesterol (mg/dl) 178 5 161 6 0.06
Triglycerides (mg/dl) 153 14 101 11 0.02
HDL cholesterol (mg/dl) 43 2 41 2 0.4
LDL cholesterol (mg/dl) 108 4.9 101 6.2 0.4
Fasting glucose (mg/dl) 118 4 112 5 0.4
Blood pressure values at the time of polysomnography.
AHI  apnea–hypopnea index; BP  blood pressure; CK  creatine kinase; CK-MB  creatine
inase-MB isoenzyme; HDL  high-density lipoprotein; LDL  low-density lipoprotein; LVEF  left
Abbreviations
and Acronyms
AHI  apnea–hypopnea
index
BMI  body mass index
BP  blood pressure
MI  myocardial infarction
OSA  obstructive sleep
apnea
PSG  polysomnography
SCD  sudden cardiac
deathentricular ejection fraction, measured within 1 week after myocardial infarction; MImyocardial
nfarction; OSA  obstructive sleep apnea. AEvery subject underwent comprehensive polysomnogra-
hy (PSG) at 17  2.4 days after MI, performed with an
ttended complete overnight polysomnographic monitoring
ystem. Obstructive apneas and hypopneas were classified
ccording to standard criteria (8). An apnea–hypopnea
ndex (AHI) 5 established the diagnosis of OSA. All
olysomnographic measurements and diagnoses were made
linded to the timing of symptoms of MI.
tatistical analysis. Patients’ characteristics are presented
s means ( SD) or percentages. Quantitative variables
ere compared with a 2-tailed t test. Qualitative data and
he frequency distributions of MI for the 4 6-h intervals of
he day between subjects with and without OSA were
ompared with the chi-square test or Fisher exact test (when
xpected frequencies below 5 occurred). Intragroup compar-
sons were conducted to determine the odds ratio of having
SA in patients who had an MI during each 6-h interval
ompared with the remaining 18 h of the day.
esults
e studied 92 patients (71 men), mean age 61  13 years
nd body mass index 30  5 kg/m2. Using a threshold of
HI 5 events/h, OSA was present in 70% of patients.
sing a more conservative threshold of AHI 10 events/h,
bout one-half (52%) of our patient population was diag-
osed with OSA. Patients’ characteristics are shown in
able 1. The 2 groups had similar prevalence of comorbidi-
ies. There was no difference between groups regarding
edication use (Tables 2 and 3).
The diurnal variation in the onset of MI in OSA
atients was different from that observed in non-OSA
atients (Fig. 1). From 12 AM to 6 AM, the frequency of
I was significantly higher in OSA patients compared with
on-OSA patients (32% vs. 7%; p  0.01). Using a
edications Taken at the Time of Myocardialnfarction, According to the Pr sence or Absencef OSA
Table 2
Medications Taken at the Time of Myocardial
Infarction, According to the Presence or Absence
of OSA
OSA (n  64) No OSA (n  28) p Value
Aspirin (%) 35 25 0.4
Beta-blockers (%) 25 29 0.7
ACE inhibitors (%) 16 21 0.5
Statins (%) 35 39 0.7
Calcium antagonists (%) 9 7 1
CE  angiotensin-converting enzyme; OSA  obstructive sleep apnea.
edications at the Time of the Sleep Study,ccording to the Presence or Abs nce of OSA
Table 3 Medications at the Time of the Sleep Study,According to the Presence or Absence of OSA
OSA (n  64) No OSA (n  28) p Value
Aspirin (%) 98 89 0.08
Beta-blockers (%) 100 96 0.3
ACE inhibitors (%) 73 78 0.6
Statins (%) 98 93 0.2
Calcium antagonists (%) 3 0 1bbreviations as in Table 2.
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July 29, 2008:343–6 Day–Night Variation of Acute MI in Obstructive Sleep Apneahreshold of AHI 10 events/h, we observed similar results
33% vs. 14%; p 0.03). From 6 AM to 12 PM, the frequency
f MI was higher in non-OSA patients compared with
SA patients (47% vs. 17%; p  0.003). Similar results
ere evident for the analyses based on three 8-h time
ntervals (Fig. 2). We found no difference in the use of
eta-blocker therapy and the frequency of MI during the
arious intervals of the day.
Patients whose MI occurred between 12 AM to 6 AM had
n odds ratio of 6 for having OSA (95% confidence interval:
.3 to 27.3, p  0.01). Of 22 patients who had an MI
etween 12 AM and 6 AM, 20 (91%) had OSA. If we used a
ore conservative threshold for OSA, the likelihood of
octurnal MI occurring in OSA patients remains signifi-
antly higher (73%).
iscussion
he novel finding of this study is that OSA patients have an
ncreased risk of MI between 12 AM and 6 AM compared
ith non-OSA patients. Our data suggest that OSA may be
trigger for MI, with a striking reversal in the expected
iurnal timing of MI onset. Conversely, non-OSA patients
ad a nadir of MI onset at night and a peak in the morning,
imilar to the diurnal distribution of MI seen in the general
opulation. Previous studies suggest that beta-blockers (7)
nd diabetes (9) may attenuate the morning peak of MI.
ur findings identify OSA as the first disease condition
ecognized to actually reverse the usual day–night variation
n the incidence of MI.
Obstructive sleep apnea has been implicated in increased
isk of MI, stroke, and SCD (10,11). Although OSA patients
ave a higher frequency of nocturnal ST-segment depression
han those without OSA (12,13), it remains unknown whether
Figure 1 6-h Epochs of MI Occurrence
Day–night pattern of myocardial infarction based on
4 6-h time intervals in OSA (n  64) and non-OSA (n  28) patients.SA may directly cause nocturnal MI. Our findings suggesthat the pathophysiology of OSA leads to an increased risk of
I during the night.
Several acute pathophysiological mechanisms during
leep in OSA patients may be responsible for their altered
iurnal variation of MI. Cessation of airflow results in
ypoxemia and hypercapnia, with consequent activation of
he chemoreflex (14) and increased sympathetic nerve ac-
ivity and blood pressure (BP) (15). Obstructed breathing
ith negative intrathoracic pressures increases cardiac wall
tress (16).
Peripheral vasoconstriction and increased cardiac output
caused by changes in cardiac transmural pressures on
ermination of apneas) lead to dramatic surges in arterial
P. These hemodynamic stresses in the setting of simulta-
eous hypoxemia and increased myocardial oxygen demand
ay promote acute nocturnal cardiac ischemia (13,17).
SA is also associated with factors that may increase the
isk of nocturnal coronary thrombosis, including platelet
ctivation during sleep (18), elevated fibrinogen levels (19),
ncreased whole-blood viscosity, and decreased fibrinolytic
ctivity (20). These processes may be responsible for the
hift in the timing of MI from the morning hours to the
ight in OSA patients.
Strengths of the current study include, first, its prospec-
ive design. Second is the use of complete PSG, interpreted
hile blinded regarding time of onset of MI. Third, the
nfluence of OSA on timing of MI onset could not be
xplained by comorbidities or medications, which were
imilar in both groups. Potential limitations include, first,
he inherent uncertainty in identifying the exact timing of
nset of an MI. The pathophysiology of coronary plaque
upture and arterial thrombosis is dynamic and occurs over
arying time periods before symptoms or signs may mani-
est. These limitations parallel those of the entire body of
Figure 2 8-h Epochs of MI Occurrence
Day–night pattern of myocardial infarction based on
3 8-h time intervals in OSA (n  64) and non-OSA (n  28) patients.
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Day–Night Variation of Acute MI in Obstructive Sleep Apnea July 29, 2008:343–6vidence that has demonstrated the timing of MI in the
eneral population and other subgroups (9). Previous stud-
es have shown a strong correlation between the timing of
I, based on cardiac biomarker levels, and the onset of pain
7). Second, based on criteria noted earlier, we did not study
very patient admitted with MI. Therefore, our data cannot
e used to estimate the overall prevalence of OSA in
atients with recent MI. Identifying the prevalence of OSA
n the post-MI patient population was not a goal of this
tudy. Nevertheless, the characteristics of our study sample
re similar to those of the general MI patient population in
lmsted County (21), and although the prevalence of OSA
n our population is relatively high, our findings are com-
arable to those noted in a prior study of OSA prevalence in
he post-MI patient population (22). A third concern relates
o whether OSA developed as an acute consequence of MI.
f patients found to have OSA on PSG, 76% had a high
isk for OSA as assessed by the Berlin Questionnaire,
uggesting that the OSA was indeed likely to have been
resent before the MI. Furthermore, PSG was conducted
hen patients were stable. Most important, this limitation
annot account for our findings of a higher nocturnal
ccurrence of MI in OSA patients. Last, these studies
epresent survivors of MI, and do not necessarily represent
ll patients with acute MI.
onclusions
n summary, we have shown that patients with OSA have
n altered diurnal variation of MI, which is consistent with
he unique nocturnal pathophysiology of OSA. These
ndings highlight a potential causative role of OSA in the
evelopment of acute coronary syndromes, and suggest that
octurnal MI may contribute to the increased likelihood of
octurnal SCD observed in OSA patients (6). Our data
urther suggest that those patients who experience the onset
f MI during the usual sleep hours should be evaluated for
he presence of OSA. Further research is necessary to
nderstand the effects of OSA therapy on modifying the
iming of MI in these patients and in altering their overall
isk of acute coronary syndromes and SCD.
eprint requests and correspondence: Dr. Virend K. Somers,
ivision of Cardiovascular Diseases, 200 First Street SW, Roch-
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